Insight Innovation: Die riskante Wette auf den ersten Impfstoff gegen Krebs
Hautkrebs könnte bald mit demselben Prinzip bekämpft werden, mit dem schon das Coronavirus gebändigt wurde. Moderna und Merck melden Erfolge mit einem mRNA-Impfstoff. Doch es gibt Hürden.
Munich - Moderna, the biotech company, celebrated its first major success in developing a completely novel medicine in 2021 amidst the raging Covid-19 pandemic. CEO Stéphane Bancel announced strong test data for a Covid-19 vaccine in May 2021. Five years later, Moderna is aiming for another medical breakthrough, this time against cancer, the most risky and expensive bet for the US biotech corporation.
The pharmaceutical world was skeptical about the project until Moderna surprisingly announced positive test results for an innovative skin cancer vaccine. Developed jointly with US pharmaceutical giant Merck & Co, the drug is the first mRNA-based therapeutic to show promise in a large, approval-relevant study. The drug could hit the market as early as 2027.
Researchers and analysts are hailing this as a scientific breakthrough. Analysts on Wall Street expect billion-dollar revenues, even tech investors are impressed. Could the same principle used to combat coronavirus soon be used to fight skin cancer?
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Insight Innovation: The Risky Bet on the First Cancer Vaccine handelsblatt.com
